Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday?
We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...
Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian ...
Garmin reported fiscal fourth-quarter 2024 revenue growth of 23% year-on-year to $1.82 billion, beating the analyst consensus estimate of $1.70 billion. The GPS navigation and wearable technology ...
Why ImmunityBio (IBRX) Is Surging Today
ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...
FDA authorizes ImmunityBio to provide rBCG to urologists amid shortages
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
FDA批准ImmunityBio膀胱癌药物扩大使用范围
加利福尼亚州卡尔弗城 - 市值24.6亿美元的免疫疗法公司ImmunityBio, Inc. (NASDAQ: IBRX )获得美国食品和药物管理局（FDA）授权，批准其扩大使用计划（EAP），为美国膀胱癌治疗提供新的卡介苗（BCG）来源。这一进展是为了应对过去一年影响患者治疗的TICE® BCG短缺问题。根据 InvestingPro ...
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.
ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.
ImmunityBio announces UK acceptance of Anktiva marketing application
ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...
ImmunityBio公布高管薪酬最新调整方案
ImmunityBio在与FDA的讨论中取得重大进展，主要涉及非肌层浸润性膀胱癌（NMIBC）和非小细胞肺癌（NSCLC）的临床开发管线。公司计划在2025年提交补充生物制品许可申请（sBLA）。